Detalhe da pesquisa
1.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285097
2.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 394(10212): 1929-1939, 2019 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31590988
3.
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
Clin Invest Med
; 42(1): E31-E38, 2019 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30904034
4.
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.
JTO Clin Res Rep
; 3(6): 100330, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35719865
5.
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Biosci Trends
; 14(1): 48-55, 2020 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023563
6.
Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value in predicting outcomes of colon liver metastases and that value's association with Beclin-1 expression.
Biosci Trends
; 11(2): 221-228, 2017 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28250335
7.
Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention.
Biosci Trends
; 10(4): 294-9, 2016 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27431004
8.
Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients.
Biosci Trends
; 9(6): 393-401, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26781797